While the common DEGs between the AML-ASXL1 and BOS datasets identified T-cell activation and T-cell differentiation among other T-cell functions as significantly enriched pathways, further analysis identified that the DEGs driving these pathways were upregulated in BOS and downregulated in AML-ASXL1, which is consistent with differential T-cell compositions between blood and bone marrow; T-cells comprise approximately 6% of lymphocytes in the bone marrow and approximately 62% in peripheral blood [45]. Here, ASXL1 is linked to acute myeloid leukemia.